Effect of creatine monohydrate in improving cellular energetics and muscle strength in ambulatory Duchenne muscular dystrophy patients: A randomized, placebo-controlled 31P MRS study

Magnetic Resonance Imaging

Volumn 28, Issue 5, 2010, Pages 698-707

  Banerjee, Bidisha ^a   Sharma, Uma ^a   Balasubramanian, Krithika ^a   Kalaivani, M ^a   Kalra, Veena ^a   Jagannathan, Naranamangalam R ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Cellular energetics; Creatine monohydrate; Duchenne muscular dystrophy; Muscle strength; Phosphorus magnetic resonance spectroscopy; Placebo

Indexed keywords

ASCORBIC ACID; CREATINE; CREATINE PHOSPHATE; PHOSPHATE; PHOSPHORUS; PLACEBO;

ANALYSIS OF COVARIANCE; ARTICLE; CELL ENERGY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG TOLERABILITY; DUCHENNE MUSCULAR DYSTROPHY; FUNCTIONAL STATUS; GENERAL CONDITION IMPROVEMENT; HUMAN; LIFESPAN; LONG TERM CARE; MUSCLE STRENGTH; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SINGLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; MALE; METABOLISM; MUSCULAR DYSTROPHY, DUCHENNE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PLACEBO EFFECT; PRESCHOOL CHILD; PROCEDURES; SKELETAL MUSCLE;

CHILD; CHILD, PRESCHOOL; CREATINE; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MUSCLE STRENGTH; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; PHOSPHORUS; PHOSPHORUS ISOTOPES; PLACEBO EFFECT;

EID: 77952959405     PISSN: 0730725X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mri.2010.03.008     Document Type: Article

References (43)

1. Moxley R.T. Corticosteroid and anabolic hormone treatment of Duchenne's muscular dystrophy. Neuromuscular disorders of infancy, childhood and adolescence 2003, 1209-1226. Butterworth Hienemann, Philadelphia. 1st ed. H.R. Jones, D.C. De Vivo, B.T. Darras (Eds.).
2. Franco A., Lansman J.B. Calcium entry through stretch inactivated ion channels in mdx myotubes. Nature 1990, 344:670-673.
3. Blake D.J., Weir A., Newey S.E., Davies K.E. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 2002, 82:291-329.
4. Berchtold M.W., Brinkmeier H., Muntener M. Calcium ion in skeletal muscle: its crucial role for muscle function, plasticity, and disease. Physiol Rev 2000, 80:1215-1265.
5. Mendell J.R., Kissel J.T., Amato A.A., King W., Signore L., Prior T.W., et al. Myoblast transfer in the treatment of Duchenne's muscular dystrophy. N Engl J Med 1995, 333:832-838.
6. Moxley R.T., Ashwal S., Pandya S., Connolly A., Florence J., Mathews K., et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy. Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005, 64:13-20.
7. Hankard R., Gottrand F., Turck D., Carpentier A., Romon M., Farriaux J.P. Resting energy expenditure and energy substrate utilization in children with Duchenne muscular dystrophy. Pediatr Res 1996, 40:29-33.
8. Hübner C., Lehr H.A., Bodlaj R., Finckh B., Oexle K., Marklund S.L., et al. Wheat kernel ingestion protects from progression of muscle weakness in mdx mice, an animal model of Duchenne muscular dystrophy. Pediatr Res 1996, 40:444-449.
9. Wyss M., Felber S., Skladal D., Koller A., Kremser C., Sperl W. The therapeutic potential of oral creatine supplementation in muscle disease. Med Hypotheses 1998, 51:333-336.
10. Wyss M., Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev 2000, 80:1107-1213.
11. Newman R.J., Bore P.J., Chan L., Gadian D.G., Styles P., Taylor D., et al. Nuclear magnetic resonance studies of forearm muscle in Duchenne dystrophy. Br Med J (Clin Res ed) 1982, 284:1072-1074.
12. 31P NMR studies in Duchenne muscular dystrophy: age related metabolic changes. Neurology 1987, 37:165-169.
13. Fitch C.D., Lucy D.D., Bornhofen J.H., Dalrymple G.V. Creatine metabolism in skeletal muscle II. Creatine kinetics in man. Neurology 1968, 18:32-42.
14. Fitch C.D., Moody L.G. Creatine metabolism in skeletal muscle V. An intracellular abnormality of creatine trapping in dystrophic muscle. Proc Soc Exp Biol Med 1969, 132:219-222.
15. Sharma U., Atri S., Sharma M.C., Sarkar C., Jagannathan N.R. Skeletal muscle metabolism in Duchenne muscular dystrophy (DMD): an in-vitro proton NMR spectroscopy study. Magn Reson Imaging 2003, 21:145-153.
16. Francaux M., Demeure R., Goudemant J.F., Poortmans J.R. Effect of exogenous creatine supplementation on muscle PCr metabolism. Int J Sports Med 2000, 21:139-145.
17. Balsom P.D., Ekblom B., Söderlund K., Sjödin B.E.H. Creatine supplementation and dynamic high intensity intermittent exercise. Scand J Med Sci Sports 1993, 3:141-149.
18. 31P MRS) in neuromuscular disorders. Ann Neurol 1991, 30:90-97.
19. 31 P magnetic resonance spectroscopy study. Neurological Res 2000, 22:145-150.
20. Walter M.C., Lochmüller H., Reilich P., Klopstock T., Huber R., Hartard M., et al. Creatine monohydrate in muscular dystrophies: a double-blind, placebo-controlled clinical study. Neurology 2000, 54:1848-1850.
21. Louis M., Lebacq J., Poortmans J.R., Belpaire-Dethiou M.C., Devogelaer J.P., Van Hecke P., et al. Beneficial effects of creatine supplementation in dystrophic patients. Muscle Nerve 2003, 27:604-610.
22. Tarnopolsky M.A., Mahoney D.J., Vajsar J., Rodriguez C., Doherty T.J., Roy B.D., et al. Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology 2004, 62:1771-1777.
23. Escolar D.M., Buyse G., Henricson E., Leshner R., Florence J., Mayhew J., et al. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Ann Neurol 2005, 58:151-155. CINRG Group.
24. Passaquin A.C., Lhote P., Rüegg U.T. Calcium influx inhibition by steroids and analogs in C2C12 skeletal muscle cells. Br J Pharmacol 1998, 124:1751-1759.
25. Lodi R., Taivassalo T. Phosphorus Magnetic Resonance Spectroscopy in the clinical investigation of muscle disorders. Clinical evaluation and diagnostic tests for neuromuscular disorders 2002, 503-534. Butterworth -Hienemann, Woburn. 1st ed. T.E. Bertorini (Ed.).
26. 31P NMR. J Biol Chem 1985, 260:3947-3954.
27. Gibbs C. The cytoplasmic phosphorylation potential. J Mol Cardiol 1985, 17:727-731.
28. Ianasescu V., Luca N., Vuia O. Respiratory control and oxidative phosphorylation in dystrophic muscle. Acta Neurol Scand 1976, 43:564-572.
29. Carpenter S., Karpati G. Skeletal muscle pathology 1984, Churchill-Livingstone, New York.
30. Taylor D.J., Kemp G.J., Radda G.K. Bioenergetics of skeletal muscle in mitochondrial myopathy. J Neurol Sci 1994, 127:198-206.
31. 31P MRS study of skeletal muscle metabolism in patients with postpolio residual paralysis. Magn Reson Imaging 2007, 25:244-249.
32. Burt C.T. Phosphodiesters and NMR: a tale of rabbits and chickens. Trends Biochem Sci 1985, 10:404-406.
33. 31P NMR studies of normal and dystrophic chicken muscle. Muscle Nerve 1984, 7:442-446.
34. 31P nuclear magnetic resonance from dystrophic chicken as l-serine ethanolamine phosphodiester. Arch Biochem Biophys 1977, 182:683-689.
35. Lucy J.A. Is there a membrane defect in muscle and other cells?. Br Med Bull 1980, 36:187-192.
36. Farias R.N., Bloj B., Moreo R.D., Sinerz F., Trucco R.E. Regulation of allosteric membrane bound enzymes through changes in membrane lipid composition. Biochim Biophys Acta 1975, 415:231-251.
37. Nagasawa T., Yonekura T., Nishizawa N., Kitts D.D. In vitro and in vivo inhibition of muscle lipid and protein oxidation by carnosine. Mol Cell Biochem 2001, 225:29-34.
38. Hankard R.G., Hammond D., Haymond M.W., Darmaun D., Persky A.M., Brazeau G.A. Clinical pharmacology of the dietary supplement creatine monohydrate. Pharmacol Rev 2001, 53:161-176.
39. Nagel B.H., Mortier W., Elmlinger M., Wollmann H.A., Schmitt K., Ranke M.B. Short stature in Duchenne muscular dystrophy: a study of 34 patients. Acta Paediatr 1999, 88:62-65.
40. Pradhan S. Valley sign in Duchenne muscular dystrophy: importance in patients with inconspicuous calves. Neurol India 2002, 50:184-186.
41. Kilmer D.D., Abresch R.T., Fowler W.M. Serial manual muscle testing in Duchenne muscular dystrophy. Arch Phys Med Rehab 1993, 74:1168-1171.
42. McDonald C.M., Abresch R.T., Carter G.T., Fowler W.M., Johnson E.R., Kilmer D.D. Sigford BJ. Profiles of neuromuscular diseases. Duchenne muscular dystrophy. Am J Phys Med Rehabil 1995, 74(5 Suppl):S70-S92.
43. Allsop K.G., Ziter F.A. Loss of strength and functional decline in Duchenne's dystrophy. Arch Neurol 1981, 38:406-411.